Table 2. Incidence rates and hazard ratios of ischemic stroke after the initiation of conventional and atypical antipsychotic medications.

						Hazard ratio (95% CI)
User Status	Mean days of follow-up (SD)	Person-Years	No. of Events	Incidence Rate per 1000 Person-Years*	Unadjusted	Propensity-score adjusted	SMR weighed	SMR weighted and Multivariable adjusted†
Class
Atypical antipsychotics(n = 444,16)	150.9(172.6)	18,350.7	62	3.42	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
Conventional antipsychotics(n = 27.168)	130.3 (153.6)	9,690.4	64	6.61	2.18(1.84–2.59)	2.71(2.01–3.52)	2.69 (2.08–3.47)	2.53 (1.95–3.27)
Generic name
Risperidone (n = 24,668)	152.7(167.2)	10,309.4	31	3.02	1 [Reference]	1 [Reference]	1 [Reference]	1 [Reference]
Quetiapine (n = 15,860)	143.9 (172.6)	6,246.2	26	4.23	1.33 (0.81–2.25)	1.35 (0.80–2.27)	1.23 (0.78–2.12)	1.01 (0.61–2.09)
Olanzapine (n = 3,888)	168.6 (202.3)	1,795.1	5	2.87	1.31 (0.47–3.24)	1.25 (0.53–2.95)	1.12 (0.59–2.75)	1.08 (0.47–2.59)
Haloperidol (n = 19,564)	131.9(151.6)	7,066.1	43	6.12	2.61(1.35–3.37)	2.64 (1.27–3.26)	2.43 (1.18–3.14)	2.09 (1.09–3.12)
Chlorpromazine (n = 7,604)	126.3 (158.3)	2,628.3	21	8.01	3.32 (2.02–6.12)	3.50 (2.17–5.65)	3.47(1.97–5.38)	3.10(1.48–5.11)

(SMR, standardized morbidity ratio)

* (No. of events/total No. of days per 365 days)× 1,000.

† Adjusted for age, gender, presence or absence of dementia (F00-F03, G30, G31.8), depression (F32–33, F34.1, F41.2), dyslipidemia (E78.0), coronary heart disease (I21-I25), COPD (J40-J44, J47), and the use of antidepressants, benzodiazepine, anticoagulants, or antithrombotic agents during the follow-up period.

SMR weighted and multivariable adjusted HR after exclusion of the patients whose propensity score was > 99.99 in quetiapine, < 0.05 in olanzapine, > 0.90 in haloperidol, and < 0.05 in chlorpromazine.